What volume of 5% dextrose (D5W) is required to dilute 160 mg of amphotericin B (deoxycholate)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Amphotericin B Deoxycholate Dilution Volume

160 mg of amphotericin B deoxycholate should be dissolved in sufficient 5% dextrose to achieve a final concentration of 0.1 mg/mL, which requires 1600 mL of D5W.

Standard Dilution Protocol

The FDA-approved preparation method follows a two-step process 1:

  1. Initial reconstitution: Add 10 mL sterile water (without bacteriostatic agent) to each 50 mg vial to create a 5 mg/mL concentrate
  2. Final dilution: Further dilute 1:50 with 5% dextrose to achieve 0.1 mg/mL final concentration

For 160 mg amphotericin B deoxycholate:

  • Final volume needed: 1600 mL of D5W
  • Final concentration: 0.1 mg/mL
  • Infusion time: 6-8 hours at 0.08 mg/kg/hour 2

Critical Preparation Requirements

The pH of D5W must exceed 4.2 before adding amphotericin B 1. Commercial D5W typically has pH ~3.7, which is below this threshold 3. If pH is below 4.2, add 1-2 mL of phosphate buffer (dibasic sodium phosphate 1.59 g + monobasic sodium phosphate 0.96 g per 100 mL water) 1.

Volume-Dependent Stability Concerns

Research demonstrates that concentration matters significantly for stability and deliverability 3:

  • 25 mg/500 mL (0.05 mg/mL): Produces excessive particles >10 μm, causes filter blockage, only 11.3% of drug delivered
  • 25 mg/250 mL (0.1 mg/mL): Meets pharmacopeial standards, flows completely
  • 50 mg/500 mL (0.1 mg/mL): Meets pharmacopeial standards, flows completely

This explains why the standard 0.1 mg/mL concentration is critical - lower concentrations risk precipitation and incomplete drug delivery.

Alternative Concentrated Preparations

For central venous line administration, higher concentrations are stable 4:

  • 0.92-1.40 mg/mL in D5W remains stable for 36 hours at both 6°C and 25°C
  • These concentrated solutions are used when fluid restriction is necessary

However, guidelines consistently recommend the standard 0.1 mg/mL dilution for peripheral administration 2, 1.

Storage and Stability

  • Standard dilution (0.1-0.25 mg/mL): Stable for 35 days at 4°C 5
  • No light protection required during storage or infusion 6
  • No bacteriostatic agent present: Use strict aseptic technique 1

Clinical Context

The 2023 Taiwan guidelines specify that amphotericin B deoxycholate (1-1.5 mg/kg/day) should be "administered in 5% dextrose with slow infusion over 6-8 h, at the rate of 0.08 mg/kg/hour" 2. This infusion rate and duration are designed to minimize infusion-related reactions while maintaining therapeutic efficacy.

Pre-medication with diphenhydramine or acetaminophen is recommended to prevent infusion reactions, and 1 L normal saline before and after infusion helps prevent nephrotoxicity 2.

Related Questions

How many milliliters of reconstituted liposomal amphotericin B should be added to each 500 mL 5% dextrose (D5W) bag, and what infusion rate in mL per hour should be used for each dose?
For a 365 mg dose of liposomal amphotericin B, should I reconstitute seven 50 mg vials with 10 mL sterile water each, withdraw 70 mL from a 500 mL 5 % dextrose (D5W) bag, add the reconstituted drug, and infuse the mixture over six hours once daily for seven days?
How should 300 mg of liposomal amphotericin B be diluted?
Should the 365 mg dose of liposomal amphotericin B for a 73‑kg adult be administered over six hours?
What baseline laboratory tests and preparations are required before administering amphotericin B lipid formulation?
What is the levothyroxine dose equivalent to 105 mg of Armour Thyroid (desiccated thyroid)?
What are the indications for obtaining a head CT in an outpatient setting?
What is the risk of cardioembolic stroke in a patient with atrial fibrillation who is not on oral anticoagulation but is receiving heparin 5,000 units every 8 hours?
What is the risk of venous thromboembolism (VTE) in patients with an intertrochanteric fracture?
In a patient who heard a pop in the calf and now has pain after an acute pickleball injury, is bedside or diagnostic ultrasound appropriate?
How should I manage a patient with a three‑day history of productive cough and fever, normal white blood cell count, platelet count, erythrocyte sedimentation rate, and a C‑reactive protein of 8.6 mg/L, who has been started on amoxicillin‑clavulanate (Amoxiclav) 650 mg three times daily?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.